Innovative Targeting Solutions Initiates Research Collaboration

BURNABY, BC, Jan. 19, 2012 /CNW/ - Innovative Targeting Solutions Inc. (ITS), the developer of the next generation fully human antibody technology (HuTARG), today announced the initiation of a research collaboration with Amgen Inc. (Thousand Oaks, CA). The agreement will allow Amgen to assess ITS's HuTARG technology for a broader potential collaboration in the future.

About Innovative Targeting Solutions Inc.
Founded in 2008, Innovative Targeting Solutions Inc. is a privately-held company that has developed a next generation platform for the generation of fully human antibody therapeutics using its proprietary HuTARG technology. The HuTARG technology is a fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. For more information, visit

SOURCE Innovative Targeting Solutions Inc

For further information:

For more information, visit

Organization Profile

Innovative Targeting Solutions Inc

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890